Essential TremorNCT06314139
Tolerability and Efficacy of Continuous Theta-burst Stimulation for Essential Tremor: A Randomized Study.
A study testing continuous theta-burst stimulation (cTBS) in people with Essential Tremor and Continuous Theta Burst Stimulation, run by West China Hospital at 1 site in China.
Trial summary
Essential tremor (ET) is one of the most common movement disorders in adults. The prevalence rate among the elderly over 65 years old is about 4.6%. Tremor usually worsens with age, leading to disability and loss of independence, which has an adverse impact on the quality of life of patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Essential Tremor, Continuous Theta Burst Stimulation
- What is being tested?
- continuous theta-burst stimulation (cTBS)
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteChina
- Study dates
- 1 Sep 2022to 1 Jun 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Aged 18 and over
- Right-hand dominant
- Were willing to participate in the trial and signed informed consent
- Essential tremor Diagnosis based on the International Parkinson and Movement Disorder Society (IPMDS) ET diagnostic criteria in 2017
Who cannot join
- A history of trauma 3 months before the onset of the disease, and it can be clearly determined that this history of trauma has led to neurological dysfunction
- Combined with other central nervous system diseases except ET
- drug or alcohol withdrawal-induced tremor, psychogenic/physiological/orthostatic/task-specific tremor
- Contraindications for undergoing cTBS, such as epilepsy history, intracranial metal implants, pacemaker installers, etc
- Skin lesions at stimulation sites
- Pregnant or breastfeeding women
Trial locations and contacts
1 site in 1 country.
China1 site
Department of Neurology, West China Hospital, Sichuan University, 37 Guo Xue Xiang, Chengdu, Sichuan Province 610041, P.R. China.
Chengdu, Sichuan, 610041
About this study
Official title: Tolerability and Efficacy of Continuous Theta-burst Stimulation for Essential Tremor: A Randomized, Double-Blind, Sham-Controlled Study.
Essential tremor (ET) is one of the most common movement disorders in adults. The prevalence rate among the elderly over 65 years old is about 4.6%. Tremor usually worsens with age, leading to disability and loss of independence, which has an adverse impact on the quality of life of patients. However, the traditional first-line treatment drugs are neither effective enough nor completely safe for ET patients. Although surgical procedures such as deep brain stimulation (DBS) and thalamotomy can be used to better control unilateral limb tremor, many patients are reluctant to choose surgical treatment because it's invasive. Therefore, there is an urgent need to develop new drugs or non-invasive therapies as a better treatment option for ET.
The pathology of the disease is not yet clear, it is generally believed that genetic, aging and environmental factors are related to ET. Hyperactivity of cerebellar function and changes of cerebello-thalamo- cortical (CTC) pathways are currently considered to be the most important pathophysiological mechanisms of ET. Therefore, the cerebellum and cortex may be the best targets for the treatment of tremor.
Continuous theta burst stimulation (cTBS) is one of the non-invasive electrophysiological techniques characterized by plexus stimulation, which is similar to low-frequency repetitive transcranial magnetic stimulation (rTMS) but closer to the physiological state of neural activity, and may inhibit the excitability of the stimulated cortex. The stimulation duration is greatly shortened, which is simpler and easier than the low-frequency rTMS of 20-30 minutes. In addition, functional near infrared spectroscopy (fNIRS) is a new non-invasive functional neuroimaging technique. It mainly uses the difference characteristics of oxyhemoglobin and deoxyhemoglobin in brain tissue for near-infrared light absorption at different wavelengths of 600-900nm. The efficacy, safety, and mechanisms involved in non-invasive stimulation therapy for ET patients are still unclear. There are few studies on the treatment of ET with cTBS, and the sample size is small (the largest sample includes only 23 ET patients). Additionally, there was a lack of exploration on the therapeutic mechanism of cTBS for ET patients. Therefore, the investigators conducted a double-blind, randomized, sham-controlled clinical trial to evaluate the safety and efficacy of cTBS in the treatment of ET patients over both cerebellar and cortical area.
Read the detailed description
Essential tremor (ET), also known as idiopathic tremor, is one of the most common movement disorders in adults. The prevalence rate among the elderly over 65 years old is about 4.6%. It is characterized by simple kinetic and/or postural tremor of the arms, with or without various combinations of midline tremors (MT)-such as the neck, voice, and facial tremors. About 30%~70% of ET patients have family history, and most of them are autosomal dominant. Tremor usually worsens with age, leading to disability and loss of independence, which has an adverse impact on the quality of life of patients. However, the traditional first-line treatment drugs are neither effective enough nor completely safe for ET patients. Although surgical procedures such as deep brain stimulation (DBS) and thalamotomy can be used to better control unilateral limb tremor, many patients are reluctant to choose surgical treatment because it's invasive. Therefore, there is an urgent need to develop new drugs or non-invasive therapies as a better treatment option for ET.
The pathology of the disease is not yet clear, it is generally believed that genetic, aging and environmental factors are related to ET. Hyperactivity of cerebellar function and changes of cerebello-thalamo- cortical (CTC) pathways are currently considered to be the most important pathophysiological mechanisms of ET. The degenerative changes of cerebellum in ET patients are prominent, such as the loss of Purkinje cells and focal axonal swelling. In addition, imaging, electrophysiological studies and clinical observations show that the cerebral cortex may also be involved. Studies have shown that the activity of cortical area is related to the frequency of tremor, and there have been reports on the disappearance of ET after cortical infarction. Therefore, the cerebellum and cortex may be the best targets for the treatment of tremor.
Transcranial magnetic stimulation (TMS) is a non-invasive electrophysiological technique for nerve stimulation and nerve regulation invented by Anthony Barker in 1985. Its principle is to use electromagnetic fields to generate induced electric fields in the brain, change abnormal brain waves of patients, and regulate the secretion of neurotransmitters and hormones closely related to emotion, cognition, sleep and other functions in the brain, so as to achieve the therapeutic effect. Continuous theta burst stimulation (cTBS) is characterized by plexus stimulation, which is similar to low-frequency rTMS but closer to the physiological state of neural activity, and may inhibit the excitability of the stimulated cortex. Moreover, the intervention time of CTBS is only 40 seconds, the stimulation intensity is lower, and the stimulation duration is greatly shortened, which is simpler and easier than the low-frequency rTMS of 20-30 minutes. The investigators hypothesized that CTBS would reduce the excitability of cerebellar cortex, thereby reducing the amplitude of tremor, and play a therapeutic role in ET patients.
Functional near infrared spectroscopy (fNIRS) is a new non-invasive functional neuroimaging technique in recent years. fNIRS mainly uses the difference characteristics of oxyhemoglobin and deoxyhemoglobin in brain tissue for near-infrared light absorption at different wavelengths of 600-900nm to directly detect the hemodynamic activities of cerebral cortex in real time, and then through observing such hemodynamic changes, discover the neurovascular coupling law, so as to deduce the neural activities of the brain. In the past 20 years, the hardware manufacturing and improvement of functional near-infrared spectroscopy technology and data processing methods have become more and more perfect, making the fNIRS technology, which uses near-infrared light to observe brain neural activities, to study various cognitive activities emerge in endlessly and develop rapidly. fNIRS is based on light intensity. Optical imaging equipment has high cost performance and is not vulnerable to electromagnetic interference from TMS pulses. It can conduct more detailed research on cortical connectivity, excitability and dynamic changes induced by cTBS.
Studies by Chuang et al. showed that after the treatment of cTBS over motor cortex or premotor cortex, the tremor amplitude of ET patients decreased significantly, but the tremor frequency remained unchanged. Hellriegel et al. included 10 ET patients and 10 healthy controls. They performed a single cTBS treatment on the primary motor cortex of the patients. They found that compared with the control group, the cTBS group reduced the total power of tremor assessed by the accelerometer, but this beneficial effect was subclinical, that is, the tremor assessment of the patients had no significant change before and after treatment. Bologna et al. included 16 ET patients and 11 healthy controls. They were treated with cTBS and sham stimulation in the right cerebellar hemisphere with crossing over after a one-week washout period. The results showed that the tremor was not significantly improved before and after CTBS treatment. They also pointed out that multiple stimuli may be effective. However, there is a lack of research on the therapeutic mechanism of cTBS in the treatment of ET. The combination of transcranial magnetic stimulation (TMS) and neuroimaging provides a new way to explore the mechanisms involved. High frequency rTMS could improve mild cognitive impairment after stroke and increase the concentration of oxyhemoglobin in prefrontal lobe. Study have observed the changes of activation mode of cerebral cortex during upper limb movement in stroke patients before and after repeated transcranial magnetic stimulation (rTMS) treatment through near infrared brain functional imaging (fNIRS). Struckmann et al. used fNIRS technology to compare the changes of prefrontal blood oxygen response in patients with depression before and after intermittent TBS treatment. They also confirmed that the oxygen and hemoglobin of patients did change before and after treatment, and further discussed the mechanism.
To sum up, there are few domestic and international clinical studies on the treatment of ET with CTBS, and the sample size is small (the largest sample includes only 23 ET patients). The results showed that the placebo effect was strong, and all of them were stimulated by single site, and the effect was not significant. Additionally, there was a lack of exploration on the therapeutic mechanism of cTBS for ET patients. Therefore, The investigators will conduct a double-blind, randomized, sham-controlled clinical trial to evaluate the safety and efficacy of cTBS in the treatment of ET patients over both cerebellar and cortical area. fNIRS technology will be applied to provide new ideas for the pathophysiological mechanism and treatment of ET.
- Being tested
- continuous theta-burst stimulation (cTBS)
- Keywords
- Essential tremor, Transcranial magnetic stimulation, Continuous theta-burst stimulation, RCT
- Medical subject headings
- Essential Tremor
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
continuous theta-burst stimulation (cTBS)Device
Continuous theta-burst stimulation (cTBS) was performed with a CCY-I Magnetic Stimulator (YIRUIDE Medical Co., Wuhan, China) with an air-cooled, figure-of-eight 70 mm coil. The site of stimulation during the TMS treatment sessions was bilateral M1 and cerebellum. Real cerebellar cTBS was delivered with the coil positioned over the cerebellar hemisphere, i.e., 3 cm laterally to and 1 cm below the inion. The cTBS protocol uses a complex pattern of stimulation consisting of three-pulse bursts at 50 Hz repeated every 200ms. A total of 600 pulses that lasts for about 40 seconds were applied which could result in a sustained reduction in corticospinal excitability that outlasted the period of stimulation by 45 min. It was delivered at an intensity corresponding to 80 % of the active motor threshold (AMT), this is the minimum stimulation intensity that evokes MEPs of approximately 200 μV in amplitude in tonically contracted muscles.
| Study group | Role | What they receive |
|---|---|---|
| cTBS group | Active comparator | cTBS at 80% action motor threshold (AMT) with 600 pulses over bilateral M1 and cerebellum. Continuous theta-burst stimulation (cTBS) was performed with a CCY-I Magnetic Stimulator (YIRUIDE Medical Co., Wuhan, China) with an air-cooled, figure-of-eight 70 mm coil. The site of stimulation during the TMS treatment sessions was bilateral M1 and cerebellum. Receives: Device: continuous theta-burst stimulation (cTBS) |
| sham group | Sham comparator | Sham stimulation was performed with the same protocol using an inactive coil to mimic true stimulation sound effects, but does not stimulate the brain or produce neurophysiological changes in cerebello-thalamo-cortical (CTC) connections and eyeblink regulation. Receives: Device: continuous theta-burst stimulation (cTBS) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Tremor assessment using Fahn-Tolosa-Marin (FTM) tremor-rating scales
The primary outcome was tremor assessment using Fahn-Tolosa-Marin tremor-rating scales (FTMTRS). All participants were assessed at baseline, 0 minutes, 10 minutes and 45 minutes post-intervention. Clinical assessment was independently performed by a neurologist specialized in movement disorder, using the Fahn-Tolosa-Marin (FTM) tremor-rating scales which comprises parts A, B and C, to evaluate severity and forms of tremor symptoms. (tremor severity: part A, specific writing/drawing tasks: part B, and functional disability: part C). Each item has 5 levels of scores (0, 1, 2, 3, and 4), representing different degrees of tremor in the patient. The total score of FTMTRS ranges from 0 to 160. The higher the score, the more severe the tremor.
Measured: All participants were assessed at baseline, 0 minutes, 10 minutes and 45 minutes post-intervention.
Secondary outcomes (2)
Clinical global impression-improvement (CGI-I) rating scores
The secondary outcome 2 was the clinical global impression-improvement (CGI-I) rating score. The CGI-I rating scale is composed of the following three parts: severity of illness (SI), global improvement (GI) and efficacy index (EI), which are used to evaluate the clinical efficacy of treatment. The severity of the disease (SI) is compared with other patients in the same study to assess the current condition of the subjects. The global improvement (GI) is to assess whether there is any change in the current condition of the evaluated patients relative to their baseline state prior to the study. Both SI and GI are scored at 8 levels of 0-7. The efficacy index comprehensively considers the efficacy and side effects of the study treatment itself, and its total score range is 0~4.0.
Measured: Clinical global impression-improvement (CGI-I) rating scores were assessed approximately 45 minutes after intervention.
Electrophysiological evaluation of cortical excitability and inhibition measured by TMS.
The secondary outcome 3 was electrophysiological evaluation of cortical excitability and inhibition measured by transcranial magnetic stimulation. Electrophysiological parameters include rest motor threshold (RMT), intracortical inhibition (ICI) with stimulation interval of 1ms and 2ms, intracortical facilitation (ICF) with stimulation interval of 12ms and 15ms, and cortical silent period (CSP).
Measured: Electrophysiological evaluation of cortical excitability and inhibition by transcranial magnetic stimulation (TMS) were assessed at baseline and approximately 45 minutes after intervention.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Mar 2024
- Study start1 Sep 2022
- Primary completion6 Apr 2023
- Study completion1 Jun 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Essential TremorStudies of the same condition, open and under way.
- More trials run by West China HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- West China Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yanming Xu, West China Hospital
- Investigators
- Xu Yanming, Study director, Department of Neurology, West China Hospital, Sichuan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06314139
- Sponsor's protocol ID
- YanmingXu001
- Status last verified
- Mar 2024
- First submitted
- 5 Dec 2023
- Last updated
- 15 Mar 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Mar 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Tolerability and Efficacy of Continuous Theta-burst Stimulation for Essential Tremor: A Randomized, Double-Blind, Sham-Controlled Study.
- ClinicalTrials.gov ID
- NCT06314139
- Acronym / sponsor ID
- YanmingXu001
- Keywords
- Essential tremor, Transcranial magnetic stimulation, Continuous theta-burst stimulation, RCT
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- West China HospitalUniversity, hospital or other
- Study start
- 1 Sep 2022 (actual)
- Primary completion
- 6 Apr 2023 (actual)
- Study completion
- 1 Jun 2023 (actual)
- First posted
- 15 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Essential tremor (ET) is one of the most common movement disorders in adults. The prevalence rate among the elderly over 65 years old is about 4.6%. Tremor usually worsens with age, leading to disability and loss of independence, which has an adverse impact on the quality of life of patients. However, the traditional first-line treatment drugs are neither effective enough nor completely safe for ET patients. Although surgical procedures such as deep brain stimulation (DBS) and thalamotomy can be used to better control unilateral limb tremor, many patients are reluctant to choose surgical treatment because it's invasive. Therefore, there is an urgent need to develop new drugs or non-invasive therapies as a better treatment option for ET.
The pathology of the disease is not yet clear, it is generally believed that genetic, aging and environmental factors are related to ET. Hyperactivity of cerebellar function and changes of cerebello-thalamo- cortical (CTC) pathways are currently considered to be the most important pathophysiological mechanisms of ET. Therefore, the cerebellum and cortex may be the best targets for the treatment of tremor.
Continuous theta burst stimulation (cTBS) is one of the non-invasive electrophysiological techniques characterized by plexus stimulation, which is similar to low-frequency repetitive transcranial magnetic stimulation (rTMS) but closer to the physiological state of neural activity, and may inhibit the excitability of the stimulated cortex. The stimulation duration is greatly shortened, which is simpler and easier than the low-frequency rTMS of 20-30 minutes. In addition, functional near infrared spectroscopy (fNIRS) is a new non-invasive functional neuroimaging technique. It mainly uses the difference characteristics of oxyhemoglobin and deoxyhemoglobin in brain tissue for near-infrared light absorption at different wavelengths of 600-900nm. The efficacy, safety, and mechanisms involved in non-invasive stimulation therapy for ET patients are still unclear. There are few studies on the treatment of ET with cTBS, and the sample size is small (the largest sample includes only 23 ET patients). Additionally, there was a lack of exploration on the therapeutic mechanism of cTBS for ET patients. Therefore, the investigators conducted a double-blind, randomized, sham-controlled clinical trial to evaluate the safety and efficacy of cTBS in the treatment of ET patients over both cerebellar and cortical area.
Detailed description
Essential tremor (ET), also known as idiopathic tremor, is one of the most common movement disorders in adults. The prevalence rate among the elderly over 65 years old is about 4.6%. It is characterized by simple kinetic and/or postural tremor of the arms, with or without various combinations of midline tremors (MT)-such as the neck, voice, and facial tremors. About 30%~70% of ET patients have family history, and most of them are autosomal dominant. Tremor usually worsens with age, leading to disability and loss of independence, which has an adverse impact on the quality of life of patients. However, the traditional first-line treatment drugs are neither effective enough nor completely safe for ET patients. Although surgical procedures such as deep brain stimulation (DBS) and thalamotomy can be used to better control unilateral limb tremor, many patients are reluctant to choose surgical treatment because it's invasive. Therefore, there is an urgent need to develop new drugs or non-invasive therapies as a better treatment option for ET.
The pathology of the disease is not yet clear, it is generally believed that genetic, aging and environmental factors are related to ET. Hyperactivity of cerebellar function and changes of cerebello-thalamo- cortical (CTC) pathways are currently considered to be the most important pathophysiological mechanisms of ET. The degenerative changes of cerebellum in ET patients are prominent, such as the loss of Purkinje cells and focal axonal swelling. In addition, imaging, electrophysiological studies and clinical observations show that the cerebral cortex may also be involved. Studies have shown that the activity of cortical area is related to the frequency of tremor, and there have been reports on the disappearance of ET after cortical infarction. Therefore, the cerebellum and cortex may be the best targets for the treatment of tremor.
Transcranial magnetic stimulation (TMS) is a non-invasive electrophysiological technique for nerve stimulation and nerve regulation invented by Anthony Barker in 1985. Its principle is to use electromagnetic fields to generate induced electric fields in the brain, change abnormal brain waves of patients, and regulate the secretion of neurotransmitters and hormones closely related to emotion, cognition, sleep and other functions in the brain, so as to achieve the therapeutic effect. Continuous theta burst stimulation (cTBS) is characterized by plexus stimulation, which is similar to low-frequency rTMS but closer to the physiological state of neural activity, and may inhibit the excitability of the stimulated cortex. Moreover, the intervention time of CTBS is only 40 seconds, the stimulation intensity is lower, and the stimulation duration is greatly shortened, which is simpler and easier than the low-frequency rTMS of 20-30 minutes. The investigators hypothesized that CTBS would reduce the excitability of cerebellar cortex, thereby reducing the amplitude of tremor, and play a therapeutic role in ET patients.
Functional near infrared spectroscopy (fNIRS) is a new non-invasive functional neuroimaging technique in recent years. fNIRS mainly uses the difference characteristics of oxyhemoglobin and deoxyhemoglobin in brain tissue for near-infrared light absorption at different wavelengths of 600-900nm to directly detect the hemodynamic activities of cerebral cortex in real time, and then through observing such hemodynamic changes, discover the neurovascular coupling law, so as to deduce the neural activities of the brain. In the past 20 years, the hardware manufacturing and improvement of functional near-infrared spectroscopy technology and data processing methods have become more and more perfect, making the fNIRS technology, which uses near-infrared light to observe brain neural activities, to study various cognitive activities emerge in endlessly and develop rapidly. fNIRS is based on light intensity. Optical imaging equipment has high cost performance and is not vulnerable to electromagnetic interference from TMS pulses. It can conduct more detailed research on cortical connectivity, excitability and dynamic changes induced by cTBS.
Studies by Chuang et al. showed that after the treatment of cTBS over motor cortex or premotor cortex, the tremor amplitude of ET patients decreased significantly, but the tremor frequency remained unchanged. Hellriegel et al. included 10 ET patients and 10 healthy controls. They performed a single cTBS treatment on the primary motor cortex of the patients. They found that compared with the control group, the cTBS group reduced the total power of tremor assessed by the accelerometer, but this beneficial effect was subclinical, that is, the tremor assessment of the patients had no significant change before and after treatment. Bologna et al. included 16 ET patients and 11 healthy controls. They were treated with cTBS and sham stimulation in the right cerebellar hemisphere with crossing over after a one-week washout period. The results showed that the tremor was not significantly improved before and after CTBS treatment. They also pointed out that multiple stimuli may be effective. However, there is a lack of research on the therapeutic mechanism of cTBS in the treatment of ET. The combination of transcranial magnetic stimulation (TMS) and neuroimaging provides a new way to explore the mechanisms involved. High frequency rTMS could improve mild cognitive impairment after stroke and increase the concentration of oxyhemoglobin in prefrontal lobe. Study have observed the changes of activation mode of cerebral cortex during upper limb movement in stroke patients before and after repeated transcranial magnetic stimulation (rTMS) treatment through near infrared brain functional imaging (fNIRS). Struckmann et al. used fNIRS technology to compare the changes of prefrontal blood oxygen response in patients with depression before and after intermittent TBS treatment. They also confirmed that the oxygen and hemoglobin of patients did change before and after treatment, and further discussed the mechanism.
To sum up, there are few domestic and international clinical studies on the treatment of ET with CTBS, and the sample size is small (the largest sample includes only 23 ET patients). The results showed that the placebo effect was strong, and all of them were stimulated by single site, and the effect was not significant. Additionally, there was a lack of exploration on the therapeutic mechanism of cTBS for ET patients. Therefore, The investigators will conduct a double-blind, randomized, sham-controlled clinical trial to evaluate the safety and efficacy of cTBS in the treatment of ET patients over both cerebellar and cortical area. fNIRS technology will be applied to provide new ideas for the pathophysiological mechanism and treatment of ET.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| cTBS group | Active comparator | Device: continuous theta-burst stimulation (cTBS)cTBS at 80% action motor threshold (AMT) with 600 pulses over bilateral M1 and cerebellum. Continuous theta-burst stimulation (cTBS) was performed with a CCY-I Magnetic Stimulator (YIRUIDE Medical Co., Wuhan, China) with an air-cooled, figure-of-eight 70 mm coil. The site of stimulation during the TMS treatment sessions was bilateral M1 and cerebellum. |
| sham group | Sham comparator | Device: continuous theta-burst stimulation (cTBS)Sham stimulation was performed with the same protocol using an inactive coil to mimic true stimulation sound effects, but does not stimulate the brain or produce neurophysiological changes in cerebello-thalamo-cortical (CTC) connections and eyeblink regulation. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Aged 18 and over
- Right-hand dominant
- Were willing to participate in the trial and signed informed consent
- Essential tremor Diagnosis based on the International Parkinson and Movement Disorder Society (IPMDS) ET diagnostic criteria in 2017
Key exclusion criteria (6 listed)
- A history of trauma 3 months before the onset of the disease, and it can be clearly determined that this history of trauma has led to neurological dysfunction
- Combined with other central nervous system diseases except ET
- drug or alcohol withdrawal-induced tremor, psychogenic/physiological/orthostatic/task-specific tremor
- Contraindications for undergoing cTBS, such as epilepsy history, intracranial metal implants, pacemaker installers, etc
- Skin lesions at stimulation sites
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| continuous theta-burst stimulation (cTBS)Continuous theta-burst stimulation (cTBS) was performed with a CCY-I Magnetic Stimulator (YIRUIDE Medical Co., Wuhan, China) with an air-cooled, figure-of-eight 70 mm coil. The site of stimulation during the TMS treatment sessions was bilateral M1 and cerebellum. Real cerebellar cTBS was delivered with the coil positioned over the cerebellar hemisphere, i.e., 3 cm laterally to and 1 cm below the inion. The cTBS protocol uses a complex pattern of stimulation consisting of three-pulse bursts at 50 Hz repeated every 200ms. A total of 600 pulses that lasts for about 40 seconds were applied which could result in a sustained reduction in corticospinal excitability that outlasted the period of stimulation by 45 min. It was delivered at an intensity corresponding to 80 % of the active motor threshold (AMT), this is the minimum stimulation intensity that evokes MEPs of approximately 200 μV in amplitude in tonically contracted muscles. | Device | cTBS group, sham group |
Primary outcome
Tremor assessment using Fahn-Tolosa-Marin (FTM) tremor-rating scales
Time frame: All participants were assessed at baseline, 0 minutes, 10 minutes and 45 minutes post-intervention.
The primary outcome was tremor assessment using Fahn-Tolosa-Marin tremor-rating scales (FTMTRS). All participants were assessed at baseline, 0 minutes, 10 minutes and 45 minutes post-intervention. Clinical assessment was independently performed by a neurologist specialized in movement disorder, using the Fahn-Tolosa-Marin (FTM) tremor-rating scales which comprises parts A, B and C, to evaluate severity and forms of tremor symptoms. (tremor severity: part A, specific writing/drawing tasks: part B, and functional disability: part C). Each item has 5 levels of scores (0, 1, 2, 3, and 4), representing different degrees of tremor in the patient. The total score of FTMTRS ranges from 0 to 160. The higher the score, the more severe the tremor.
2 secondary outcomes
Clinical global impression-improvement (CGI-I) rating scores
Time frame: Clinical global impression-improvement (CGI-I) rating scores were assessed approximately 45 minutes after intervention.
Electrophysiological evaluation of cortical excitability and inhibition measured by TMS.
Time frame: Electrophysiological evaluation of cortical excitability and inhibition by transcranial magnetic stimulation (TMS) were assessed at baseline and approximately 45 minutes after intervention.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Mar 2024.
Related trials for Essential Tremor
RecruitingObservational study
The Encora X1™ in a Real World Observational Study
Essential Tremor
Recruiting
Deep Brain Stimulation Surgery for Movement Disorders
Parkinson's Disease, Essential Tremor
RecruitingObservational study
Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease
Essential Tremor, Movement Disorders, Essential Tremor
Recruiting
Effects of Microelectrode-based Brain Stimulation in Humans
Essential Tremor, Parkinsons Disease (PD)
Active, not recruitingObservational study
Identifying Markers of Disease Subtypes and Disease Progression in the Syndrome of Essential Tremor
Essential Tremor
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Xu Yanming study director
Department of Neurology, West China Hospital, Sichuan University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing continuous theta-burst stimulation (cTBS) in people with Essential Tremor and Continuous Theta Burst Stimulation, run by West China Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Tremor assessment using Fahn-Tolosa-Marin (FTM) tremor-rating scales (time frame: All participants were assessed at baseline, 0 minutes, 10 minutes and 45 minutes post-intervention.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Mar 2024.